Nurse-Led Initiatives to Improve Patient Care
Speakers discussed nurse-led initiatives to improve patient care during a session at the 43rd Annual Congress in Washington, DC.
Providing Quality Healthcare to Different Patient Populations
During a session at the 43rd Annual Congress in Washington, DC, various speakers discussed their work in providing quality health care to vulnerable patient populations.
Nurses Are Advancing Research in Data-Powered Science
Nurses can foster data-powered health through getting involved in research and ensuring that data collection is in patients’ best interest and accessible to all. Patricia Brennan, PhD, RN, director of the National Library of Medicine, and Suzanne Bakken, PhD, RN, FAAN, a professor at Columbia University, discussed how data can empower health and what nurses can do to advance research during a session at the 43rd Annual Congress in Washington, DC.
Follow These Nursing Best Practices in Managing Patients Receiving CAR T-Cell Therapy
Kathleen McDermott, RN, BSN, OCN®, BMTCN®, of the Dana-Farber Cancer Institute, and coauthors presented the background for axicabtagene ciloleucel’s approval and nursing best practices for managing patients receiving CAR T-cell therapy during a poster session at the ONS 43rd Annual Congress in Washington, DC.
- Read more about Follow These Nursing Best Practices in Managing Patients Receiving CAR T-Cell Therapy
- Add new comment
ONS 43rd Annual Congress Opening Honors Oncology Nurses’ Compassion, Innovation, and Dedication
Keynote speaker Lee Tomlinson, founder of the C.A.R.E. Effect, discussed his journey from cancer survivor to patient advocate, calling for compassionate care and thanking nurses for being the reason he is alive today, during the opening session at the 43rd Annual Congress in Washington, DC, on Thursday, May 17, 2018.
- Read more about ONS 43rd Annual Congress Opening Honors Oncology Nurses’ Compassion, Innovation, and Dedication
- Add new comment
When Good Nurses Say Bad Things: Fighting Professional Incivility
Professional incivility, rudeness, and bullying are not new to the world of nursing. Nurses can see escalated teasing or bullying as “a rite of passage” or “earning our stripes.” However, changes in the workplace have shown that no matter what it’s called, bullying and professional incivility has no place in the working environment. Anne Ireland, MSN, RN, AOCN®, CENP, clinical director of the Solid Tumor Program at City of Hope National Medical Center in Duarte, CA, and Tracy Gosselin, PhD, RN, AOCN®, NEA-BC, chief nursing and patient care services officer at Duke University Hospital in Durham, NC, gave a lecture at the 43rd Annual Congress in Washington, DC, on their work with professional incivility and bullying and ways to teach nurses how to intervene and become powerful bystanders.
Using the Social Network: What Are the Professional Boundaries?
It’s hard to imagine life without social media, even though the active use of it is less than 15 years old. People use social media to stay connected to family and friends, for information on communities, and more. And although social media is most often used as a personal outlet, it has become much more prevalent in the professional realm as well.
Nurse Scientists Are Promoting the Future of Cancer Nursing Research at NINR and NCI
Many programs at the National Cancer Institute (NCI) are focused on cancer research, and support for cancer- and treatment-related symptoms and toxicities crosses a number of National Institutes of Health (NIH) organizations. Martha Matocha, PhD, program director and team lead of the National Institute of Nursing Research (NINR), and Ann O’Mara, PhD, RN, FAAN, program officer at NCI, provided tips and opportunities for nurses and how they can conduct or participate in cancer research programs during a session at the 43rd Annual Congress in Washington, DC.
- Read more about Nurse Scientists Are Promoting the Future of Cancer Nursing Research at NINR and NCI
- Add new comment
FDA Approves Epoetin Alfa-Epbx as a Biosimilar to Epoetin Alfa
On May 15, 2018, the U.S. Food and Drug Administration approved epoetin alfa-epbx (Retacrit™) as a biosimilar to epoetin alfa (Epogen/Procrit) for the treatment of anemia due to chronic kidney disease.
Huntington Disease May Hold Key to Novel Cancer Treatment
The mutated huntington (HTT) gene causes the body to generate a class of small molecules that are toxic to cancer cells but not most healthy cells, according to the results of a new study published in EMBO Reports. The researchers went as far as to call it a “super assassin against all tumor cells.”